Malta - English - Medicines Authority

hospira uk limited - cytarabine - solution for injection - cytarabine 100 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

hospira uk limited - cytarabine - solution for injection - cytarabine 100 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

hospira uk limited - cytarabine - solution for injection - cytarabine 100 mg/ml - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - nevirapine 200mg (based on 100% assay and nil water content);   - tablet - 200 mg - active: nevirapine 200mg (based on 100% assay and nil water content)   excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified water sodium starch glycolate - use in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults. resistant virus emerges rapidly and uniformly when nevirapine is administered as monotherapy. therefore, it should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - nevirapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; colloidal anhydrous silica; sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose - nevirapine in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and adolescents over the age of 16 years.,resistant virus emerges rapidly when nevirapine is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, nevirapine should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - nevirapine -

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - nevirapine (unii: 99dk7fvk1h) (nevirapine - unii:99dk7fvk1h) - nevirapine extended-release tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adults and pediatric patients 6 years of age or older with a body surface area (bsa) of 1.17 m2 or greater [see clinical studies (14.1, 14.2)] . limitations of use: based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine extended-release tablets are not recommended to be initiated, unless the benefit outweighs the risk, in: - adult females with cd4+ cell counts greater than 250 cells/mm3 or - adult males with cd4+ cell counts greater than 400 cells/mm3 [see warnings and precautions (5.1)] . nevirapine extended-release tablets are contraindicated: - in patients with moderate or severe (child-pugh class b or c, respectively) hepatic impairment [see warnings and precautions (5.1) and use in specific populations (8.7)]. - for use as part of occupational and non-occupational post-exp

Malta - English - Medicines Authority

accord healthcare limited - nevirapine, anhydrous - prolonged-release tablet - nevirapine, anhydrous 400 mg - antivirals for systemic use

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - nevirapine, anhydrous - prolonged-release tablet - nevirapine, anhydrous 400 mg - antivirals for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - cytarabine - solution for inj/inf - 100 mg/ml - cytarabine